Skip to content

Evaluation of analgesic effect of diluted lidocaine spray in reducing pain caused by burning debridement in burning patients admitted to Ali-ebn Abitaleb Hospital in Zahedan between 2022 and 2023

Evaluation of analgesic effect of diluted lidocaine spray in reducing pain caused by burning debridement in burning patients admitted to Ali-ebn Abitaleb Hospital in Zahedan between 2022 and 2023

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231126060194N1
Enrollment
60
Registered
2024-02-14
Start date
2023-12-05
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after a burn. Acute pain due to trauma

Interventions

Intervention 1: Intervention group: The group that receiving lidocaine medicine. Intervention 2: Control group: The group that receiving pethidine drug.

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Informed and free consent to participate in the study 2. Burn severity above 10% 3. Patients admitted to the burn department of Ali Bin Abi Talib Zahedan Hospital

Exclusion criteria

Exclusion criteria: 1. Impaired level of consciousness (GCS < 15) 2. Hemodynamic disturbance during drug injection (SBP = 90 and PR = 60 and RR = 8 and = 90% (O2) and in patients with blood pressure (SBP = 180) or (SBP = 100) ) 3. Use of drugs or alcohol or sedatives or pain relievers in the last 48 hours 4. History of taking MAOI, TCA, SSRI, phenothiazines or sleeping pills 5. Suffering from chronic diseases (congenital or acquired heart diseases, heart failure chronic liver disease, biliary tract diseases, kidney failure and chronic lung disease) according to history and clinical examination 6. Asthma according to history and clinical examination 7. Allergy to lidocaine and pethidine 8. Weight more than 100 kg 9. Lack of consent to enter the study 10. Patient's lack of cooperation

Design outcomes

Primary

MeasureTime frame
Change in the amount of pain reported by the patient (pain measured by visual observation). Timepoint: The pain level will be asked and recorded at times 0, 5, 10, 20, 30, and 60 minutes. Method of measurement: VAS criterion.

Secondary

MeasureTime frame
Analgesia onset time in patients receiving lidocaine and IV pethidine. Timepoint: Time after starting to receive lidocaine (in minutes). Method of measurement: Time in minutes.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmasoumeh abbasnjad

Zahedan University of Medical Sciences

Amiralidivsalar@gmail.com0543337215

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026